Emerging threat of Oropouche virus: Clinical features, experimental models, and virulence Authors: Cigdem Alkan, Tetsuro Ikegami Published: 2026 ABSTRACT ABSTRACTOropouche fever, caused by Oropouche virus (OROV) and transmitted primarily by Culicoides midges, has historically been considered a neglected tropical disease characterized by an acute, self-limiting febrile illness and occasional meningoencephalitis, mostly within or along the Amazon rainforest. However, the explosive 2023–2025 outbreak expanded well beyond the Amazon region, including into the Caribbean, and was associated with a broader clinical spectrum encompassing meningoencephalitis, Guillain – Barré syndrome, persistent viral infection, lethal hemorrhagic fever, fetal loss, and neonatal abnormalities. Experimental animal models of OROV infection are available; however, substantial variation in host susceptibility across species complicates the interpretation of pathogenic mechanisms. The major virulence factor, the NSs protein, mediates inhibition of host cellular transcription, whereas the biological functions of the NSm protein remain largely unknown. This review outlines current knowledge on OROV outbreaks, clinical features, animal models, and virulence determinants, underscoring major knowledge gaps in understanding OROV virulence and pathogenesis.KEYWORDS: Oropouche virus, neuroinvasive disease, Guillain-Barré Syndrome, microcephaly, NSs, experimental models Introduction Oropouche fever is an emerging arboviral disease in the Americas caused by Oropouche virus (OROV; Orthobunyavirus oropoucheense), a member of the Simbu serogroup in the genus Orthobunyavirus, family Peribunyaviridae, order Elliovirales [1,2]. OROV is a negative-sense, single-stranded RNA virus, with a tripartite genome consisting of Large (L), Medium (M), and Small (S) segments. The L segment encodes the RNA-dependent RNA polymerase (L protein), the M segment encodes the two virion glycoproteins Gn and Gc and a nonstructural protein (NSm), and the S segment contains genes for the nucleocapsid (N) protein and a small nonstructural protein (NSs), which are expressed from overlapping reading frames. OROV infection typically causes febrile illness with severe headache and, occasionally, meningitis or meningoencephalitis. Since the first identification in Trinidad in 1955, OROV circulates predominantly in the Amazon region in Brazil. Over the past 60 years, more than 30 outbreaks have been reported across South and Central America, affecting an estimated half a million people [3]. Historically, outbreaks have been recurrent in northern and northeastern Brazil, with sporadic cases in Peru, Panama, Ecuador, Colombia, Bolivia, French Guiana, and Haiti, reflecting low-level endemic circulation and regional spread. During 2024–2025, OROV outbreaks reached unprecedented scale and geographic distribution, with over 29,000 confirmed cases, at least nine deaths, neurological complications, and vertical transmission events [4,5]. The recent Oropouche fever outbreak showed that infected air travelers could carry OROV to Europe, the United States, and Canada, where competent vectors may exist, potentially posing a risk to tourism-dependent economies, although this did not result in local endemicity [6]. There are currently no licensed antivirals or vaccines available for human use, and the virological and pathological characteristics of OROV remain insufficiently defined. Experimental models using mice and hamsters have provided insights into OROV pathogenesis: in mice, susceptibility is age-dependent, with lethal disease typically requiring disruption of innate immunity [7], whereas hamsters can develop lethal disease without such manipulation [8]. In addition, reassortment events with uncharacterized Simbu group orthobunyaviruses may alter viral phenotypes and influence susceptibility to antiviral or vaccine candidates [9–12]. In this review, we provide an overview of OROV outbreaks and viral isolates, describe the clinical manifestations of Oropouche fever in humans, nonhuman primates, and experimental animals, and summarize current insights into viral virulence factors. Given the recent emergence of Oropouche fever and reports of acute cases in travelers returning from endemic regions, a comprehensive review would be valuable for researchers and public health authorities worldwide. Documented Oropouche fever outbreaks prior to 2023 OROV (TRVL9760 strain) was first isolated in 1955 in Trinidad and Tobago from the serum of a febrile patient residing in Vega de Oropouche who had been working at a charcoal pit in the nearby Melajo Forest for two weeks prior to illness onset [13]. Since 1961, numerous Oropouche fever outbreaks have occurred across northern Brazil. From the 1960 s to the 1980 s, large outbreaks were concentrated mainly in Pará and Amazonas, with case numbers ranging from several thousand to over 100,000 (Figure 1(A), Table 1) [14]. After the large outbreaks in Rondônia in 1991, outbreaks became smaller in scale [15–19], while OROV infection was also detected in febrile patients outside the Amazon region, including São Paulo, Mato Grosso, and Bahia between 2010 and 2017 [20–22]. These observations indicate that the virus continued to circulate within the Amazon region, with occasional spillovers into non-Amazon areas prior to the 2023–2025 outbreak. Prior to the 2023–2025 outbreak, multiple local outbreaks were reported outside Brazil (Figure 1A,B, Table 2). In Panama, outbreaks occurred in Chame and San Miguelito in 1989 and in Chilibre in 1990 [14]. In Peru, OROV was first detected in the city of Iquitos in 1992 [14], followed by reports among northern military personnel in 1994 [23], Puerto Maldonado in 1994 [24], and the locality of Bagazán in 2010 [25]. More recently, outbreaks were reported in Madre de Dios (2015–2016) [26], Cusco (2016) [27], and Huánuco (2016) [28]. Additional outbreaks or sporadic cases have been documented in Argentina (2005) [29], Ecuador (2016) [30,31], Haiti (2014) [32], French Guiana (2020) [33], and Colombia in 2017 [34] and 2019–2020 [35]. Additionally, serological studies detected OROV-specific antibodies in human sera Bolivia and Ecuador collected from 2005 to 2007 and from 2003 to 2007, respectively [36]. Geographic distribution of Oropouche fever outbreaks.(A) Geographical locations of cities (red circles) and provinces, states, or administrative regions (red squares) with past Oropouche fever outbreaks are shown for Brazil (locations in blue) and parts of Peru, Colombia, and French Guiana (locations in red). ac, Acre; al, Alagoas; AP, Amapá; am, Amazonas; BA, Bahia; CE, Ceará; DF, Distrito Federal; es, Espírito Santo; GO, Goiás; ma, Maranhão; MT, Mato Grosso; MS, Mato Grosso do Sul; MG, Minas Gerais; PA, Pará; PB, Paraíba; PR, Paraná; PE, Pernambuco; PI, Piauí; RJ, Rio de Janeiro; RN, Rio Grande do Norte; RS, Rio Grande do Sul; RO, Rondônia; RR, Roraima; sc, Santa Catarina; SP, São Paulo; se, Sergipe; to, Tocantins. Brazilian states that have experienced Oropouche fever outbreaks during 2023–2025 are indicated in yellow. Image adapted from Shutterstock. Green and pink areas represent forest and deforestation, respectively. This template image does not reflect current deforestation status. (b) Countries with Oropouche fever outbreaks in Central America and the Caribbean are shown in red, and countries with potential OROV transmission are shown in black. Illustration created with BioRender.com. Table 1.Oropouche fever outbreaks in Brazil.YearsLocationsRegionsEstimated casesRef1961Belém (PA)A, 1/4~11,000*141967Bragança and Caratateua (PA)A, 1/46,400*141972Baião (PA)A, 2>85*141975Mojui dos Campos/Santarém / Belterra (PA) and othersA, 1/2/4~17,320*141978Various locations (PA)A>2,000*141979Belém (PA)A, 1/427,000*141980Belém (PA)A, 1/410,2000*141980Mazagão (AP)A, 1/4NR141980/81Manaus (AM)A, 1/4~97,000*141988Porto Franco (MA)A/B, 2/3>128*141991Ariquemes (RO)A, 2/458,574*141991Ouro Preto do Oeste (RO)A, 2/435,413*141993/94Serra Pelada (PA)A, 2~5,000152003/04Porto de Moz and Parauapebas (PA)A, 1/2/4≥93172006Magalhães Barata and Maracanã (PA)A, 1/4~18,000162007/08Manaus (AM)A, 1/4128182009Mazagão (AP)A, 1/4425192010Ribeirão Preto (SP)B, 42202011/12Cuiabá / Várzea Grande/Nova Mutum (MT)B, 3/4≥5202015Tefé (AM)A, 1/2/4≥9222016/17Salvador (BA)B, 3/45212023AC, AM, ES, MS, PA, PR, RJ, RO, RR, RS, SPA/B, 1/2/3/4832392024/25AC, AL, AM, AP, BA, CE, DF, ES, MA, MG, MS, MT, PA, PB, PE, PI, PR, RJ, RO, RR, SC, SE, SP, TOA/B, 1/2/3/425,6734,5Regions and land cover are coded as follows: A, Amazon; B, Non-Amazon; 1, Forest; 2, Scattered forest; 3, Non-forest; 4, Urban. Asterisk (*) denotes estimated number of infections (Tesh R.B. 1994). Abbreviations: AC (Acre), AL (Alagoas), AM (Amazonas), AP (Amapá), BA (Bahia), CE (Ceará), DF (Federal District), ES (Espírito Santo), MA (Maranhão), MG (Minas Gerais), MS (Mato Grosso do Sul), MT (Mato Grosso), PA (Pará), PB (Paraíba), PE (Pernambuco), PI (Piauí), PR (Paraná), RJ (Rio de Janeiro), RO (Rondônia), RR (Roraima), RS (Rio Grande do Sul), SC (Santa Catarina), SE (Sergipe), SP (São Paulo), and TO (Tocantins). NR represents not reported. Oropouche fever outbreaks in Brazil. Regions and land cover are coded as follows: A, Amazon; B, Non-Amazon; 1, Forest; 2, Scattered forest; 3, Non-forest; 4, Urban. Asterisk (*) denotes estimated number of infections (Tesh R.B. 1994). Abbreviations: AC (Acre), AL (Alagoas), AM (Amazonas), AP (Amapá), BA (Bahia), CE (Ceará), DF (Federal District), ES (Espírito Santo), MA (Maranhão), MG (Minas Gerais), MS (Mato Grosso do Sul), MT (Mato Grosso), PA (Pará), PB (Paraíba), PE (Pernambuco), PI (Piauí), PR (Paraná), RJ (Rio de Janeiro), RO (Rondônia), RR (Roraima), RS (Rio Grande do Sul), SC (Santa Catarina), SE (Sergipe), SP (São Paulo), and TO (Tocantins). NR represents not reported. Table 2.Oropouche fever outbreaks outside Brazil.CountriesYearsLocationsRegionsCasesRefTrinidad and Tobago1955Vega de OropoucheB, 2≥113Panama1989Chame; San MiguelitoB, 3/4NR14 1990ChilibreB, 3NR14 2024/25Darién*; East Panama*B, 1/2/35174,5Peru1992IquitosA, 1/4≥514 1994Puerto MaldonadoA, 1/4NR24 1994Unknown (Army troop)A, 16**23 2010San MartínA, 2NR25 2015/16Madre de Dios*A, 1/2/412226 2016Cusco*A/B, 2/3/46127 2016Huánuco*A/B, 2/3/44628 2024/25Loreto*; Madre de Dios*; Ucayali*; Huánuco*; Junín*; San Martín*; Tumbes*; Cusco*; Puno*; Ayacucho*; Cajamarca*; Amazonas*A/B, 2/3/41,5934,5Colombia2017TurbacoB, 3134 2019/20Leticia; Villavicencio; Cali; CúcutaA/B, 2/48735 2024Amazonas*; Meta*; Caquetá*; Vaupés*; Tolima*; Córdoba*; Huila*A/B, 2/31004,5Ecuador2003/07GuayaquilB, 41**30 2016Esmeraldas*B, 2/4631 2024/25Morona Santiago*; Bolívar*; Los Ríos*A/B, 2/334Haiti2014Ouest*B, 3/4132French Guiana2020SaülA, 22333Bolivia2005/07Cochabamba*B, 2/4≥2**36 2024La Paz*; Beni*; Pando*A/B, 2/33564Argentina2025Jujuy*B, 3NR29Guyana2024/25Mahaica-Berbice*B, 344,5Venezuela2025Miranda*; Barinas*; Portuguesa*B, 3/455Barbados2024Saint Lucy*; Saint Thomas*B, 324Cuba2024/25Havana*; Santiago de Cuba*; Pinar del Rio*; Cienfuegos*; Matanzas*; Villa Clara*; Guantánamo*; Artemisa*; Ciego de Ávila*; Camagüey*; Las Tunas*B, 3/46544,5Regions and land cover are coded as follows: A, Amazon; B, Non-Amazon; 1, Forest; 2, Scattered forest; 3, Non-forest; 4, Urban. Asterisk (*) indicates province, state, or administrative region, and double asterisk (**) indicates seropositive cases. NR represents not reported. Oropouche fever outbreaks outside Brazil. Regions and land cover are coded as follows: A, Amazon; B, Non-Amazon; 1, Forest; 2, Scattered forest; 3, Non-forest; 4, Urban. Asterisk (*) indicates province, state, or administrative region, and double asterisk (**) indicates seropositive cases. NR represents not reported. Documented Oropouche fever outbreaks, 2023–2025 OROV outbreaks, which began in late 2023, remained endemic in Brazil that year and expanded to an unprecedented scale and geographic spread across the Americas, the Caribbean, North America, and Europe during 2024–2025 (Figure 1, Tables 1, 2 , and 3) [5,37–40]. During the 2024–2025 period, at least 29,069 cases were reported, and Brazil accounted for the majority of cases (25,263), followed by Peru (1,593), Cuba (654), Panama (517), Bolivia (356), Colombia (100), Venezuela (5), Guyana (4), Ecuador (3), and Barbados (2). At least 162 imported cases were reported in the United States, Canada, Germany, France, Italy, Spain, the United Kingdom, Chile, Uruguay, and the Cayman Islands, linked to international travelers returning from Cuba, Brazil, Panama, Colombia, Dominica, and Guatemala [4,5,38,40]. No Oropouche fever outbreaks have been reported in Dominica or Guatemala; however, OROV infections in returning travelers suggest possible undetected viral transmission in these countries during 2024–2025. During 2024–2025, at least nine deaths were reported (four in 2024 including two in Bahia, one in Paraná, and one in Espírito Santo; and five in 2025, including one in Espírito Santo and four in Rio de Janeiro). In addition, previously unrecognized clinical manifestations were observed, including frequent neurological complications, neonatal abnormalities associated with infection during pregnancy, and evidence of viral persistence in infected patients. Fetal and neonatal deaths have also been reported in association with vertical transmission of OROV in pregnant women [41]. Table 3.Imported Oropouche fever cases, 2024–2025.CountriesTravel DestinationsCasesRefCanadaCuba, Colombia34,5United StatesCuba, Panama1094,5GermanyCuba, Dominica44,5,38FranceCuba, Brazil75,38ItalyCuba, Brazil84,5,38SpainCuba, Guatemala234,5,38United KingdomBrazil35,38ChileBrazil25UruguayBrazil35Cayman IslandsCuba14Cases in travelers to the Netherlands, Sweden, Austria, and others (Ref.38) are not shown in the Table. Imported Oropouche fever cases, 2024–2025. Cases in travelers to the Netherlands, Sweden, Austria, and others (Ref.38) are not shown in the Table. Isolation of viruses from arthropods and wild animals Following its initial isolation from a febrile human patient, OROV was later recovered from a pool of Coquillettidia (Cq.) venezuelensis mosquitoes in Trinidad in 1960 [13], and a pool of Aedes (Ae.) serratus in Brazil in 1960, and from the blood of a three-toed sloth, Bradypus (B.) tridactylus [42]. These early finding suggested a sylvatic transmission cycle involving forest-dwelling mosquitoes and vertebrate hosts. OROV was later isolated from Culex (Cx.) quinquefasciatus mosquitoes and Culicoides (C.) paraensis (biting midge) [19,43,44], indicating the potential for spillover into peri-urban and urban environments. Field studies showed very low isolation rates from insects, ranging from 0.01% to 0.17% for Cx. quinquefasciatus and 0.01% to 0.03% for C. paraensis across multiple locations in Brazil from the 1960 s to 1980 s [43–45], suggesting that natural infection is relatively rare but sufficient to sustain transmission under favorable conditions. Under experimental conditions, Cx. quinquefasciatus rarely transmitted OROV (BeAn 19,991) from viremic hamsters to naïve hamsters, occurring in only two animals across three trials despite multiple engorged bites and requiring high virus titers (9.5–9.9 log10 SMLD50/mL), indicating limited efficiency as a vector [46]. In contrast, C. paraensis efficiently transmitted OROV after feeding on viremic hamsters (6.7–8.3 log10 SMLD50/mL), even with a single bite [47]. C. paraensis midges feeding on febrile patients with viremia of 6.3–7.3 log10 SMLD50/mL became readily infected (34%), and approximately half of these transmitted the virus to hamsters, supporting their role as the primary urban vector [48]. Consistent with this, Culicoides (C.) sonorensis, a species common in the western United States [49], exhibited high infection (86.6%), dissemination (83.1%), and measurable transmission (13.9%) after oral exposure to OROV TRVL9760, serving as a useful experimental surrogate for C. paraensis [50]. Following the 2023–2025 outbreak, C. paraensis was reported in multiple Cuban cities, including Santiago de Cuba, Cienfuegos, and Havana [51], highlighting its broader geographic distribution and potential for urban transmission beyond endemic regions. Taken together, available evidence supports a dual transmission system in which C. paraensis sustains the urban cycle of OROV transmission, while the sylvatic cycle likely involves forest-associated mosquitoes such as Cq. venezuelensis and Ae. serratus, along with vertebrate hosts including sloths and possibly non-human primates. However, the specific vectors and dynamics of the sylvatic cycle remain incompletely defined, and the extent to which bridge vectors facilitate spillover between sylvatic and urban settings requires further investigation. OROV has been repeatedly isolated from sloths (B. tridactylus) in Brazil [19,43], supporting their role as potential reservoir or amplifying hosts in the sylvatic cycle. In 2000, OROV (BeAn 626,990, Genotype III) was also isolated from a tissue suspension of a Callithrix monkey in Arinos, Minas Gerais State, in southeastern Brazil [52], further implicating nonhuman primates in virus maintenance. Together, these findings suggest that multiple mammalian hosts may contribute to enzootic circulation. Reassortment, which is the exchange of genome segments between two segmented RNA viruses during co-infection of a single host cell [53], is a key evolutionary mechanism in orthobunyaviruses and contributes to viral diversification and emergence. Interestingly, reassortment has been documented for OROV in several studies, with newly generated reassortants within the Simbu or Bunyamwera serogroups often inheriting the L and S segments from one parental virus and the M segment from the other [54]. Several naturally occurring reassortants illustrate this pattern. Two OROV-related viruses (BeAn 790 and BeAn 789,726) were isolated from black-tufted marmosets (Callithrix penicillata) in Minas Gerais State in 2012 [55]. These two OROV-related viruses, designated Perdões virus (PDEV), carry S- and L-segments similar to OROV, while their M-segment appears to be derived from an as-yet unidentified Simbu-group orthobunyavirus. Madre de Dios virus (MDDV), which contains the OROV S- and L-segments and an M-segment from an as-yet unidentified Simbu-group orthobunyavirus, was first isolated from a febrile patient in the Madre de Dios region, Peru in 2007 [9] and later from a moribund white-faced capuchin monkey (Cebus olivaceus) near Atapirire, Venezuela, in 2010 [56]. A comparable M-segment reassortant, Jatobal virus (JATV; BeAn 423,380), was also isolated from a ring-tailed coati (Nasua nasua), a medium-sized South American carnivore, in Para, Brazil in 1985 [10,11]. Moreover, another M-segment reassortant, Iquitos virus (IQTV), was isolated from febrile patients in Iquitos, Peru between 1995 and 2006 [12]. Collectively, these findings indicate that nonhuman primates and other mammals are susceptible hosts and may permit co-infection with OROV and related viruses, providing opportunities for reassortment. However, it is unclear whether these reassortant viruses utilize C. paraensis or other arthropods as vectors, particularly within sylvatic versus urban transmission cycles. Furthermore, although all three genomic segments are theoretically exchangeable [53], several studies have reported reassortants involving the M segment. The mechanisms underlying segment exchange remain unclear and require further investigation. Evolutionary lineages of Oropouche virus Phylogenetic analyses of nucleotide sequences indicate that each OROV genome segment has distinct evolutionary lineages: four in the S segment, three in the M segment, and two in the L segment [19]. Historically, genotypes I – IV have been defined based on S-segment phylogeny [19,20,57], which has the most extensive sequence availability. Among the four recognized OROV genotypes, genotype I is the most widespread, circulating across multiple regions of Brazil, including Acre, Amazonas, Maranhão, Mato Grosso, and Pará, and extending to Trinidad and Tobago. In contrast, genotype II shows a more regionally concentrated but still cross-border distribution, with detections in northern Brazil and neighboring countries such as Peru, Ecuador [58], and Colombia [35]. Genotype III has been identified less frequently, with sporadic reports from Brazil such as Acre, Minas Gerais [52], and Rondônia, and Panama, suggesting more limited circulation. Notably, genotype IV appears to be rare and geographically restricted, having been reported only once from a historical sample collected in Amazonas, Brazil, in 1980. The three OROV genome segments exhibit distinct evolutionary patterns, reflecting differences in divergence, evolutionary rates, and functional constraints. The mean genetic divergence for the N, Gn, and L genes among different OROV strains was reported as 6.8% (amino acid: 3.9%), 5.6% (3.8%), and 0.8% (0%), respectively [19]. Molecular phylogenetic and molecular clock analyses revealed geographically structured viral populations and evidence of frequent genome reassortment among segments. The L and M segments show deep evolutionary divergence and clear lineage structure, whereas the S segment exhibits weaker phylogenetic resolution [58]. Differences in divergence and evolutionary rates among segments, particularly the M segment having the oldest origin but slowest rate, suggest distinct selective constraints and functional pressures. The study also identified reassortment, particularly in the 2009 Mazagao outbreak lineage, as indicated by incongruent segment phylogenies, evidence of positive selection in N, Gn, NSm, and Gc, including key antigenic residues in Gc (T145 and G269), and lineage-specific N linked glycosylation sites, with residue 133 in the M segment of lineage I and residue 218 in lineage II [58]. An extensive sequencing analysis of viruses from 382 patients in Brazil (Amazonas, Acre, Rondônia, and Roraima) collected between 2022 and 2024 revealed a monophyletic clade designated OROV BR-2015–2024 [59]. This clade represents a reassortant, with the S and L segments (S2 and L2 lineages) derived from the OROV PE/CO/EC-2008–2021 clade circulating in Peru, Colombia, and Ecuador during 2008–2021, and the M segment (M1 lineage) closely related to the OROV BR-2009–2018 clade detected in Amapá (2009) and Pará (2018). All L, M, and S genomic sequences are available from outbreaks in French Guiana (2020) and Tefé, Amazonas (2015), providing evidence that reassortment occurred between these viral lineages. This event is estimated to have occurred between 2009 and 2013 [59]. This reassortment might have facilitated the geographic expansion of OROV. During the 2023–2025 outbreak, viruses found outside the Amazon belonged to subgroups closely related to three major lineages circulating in urban centers in Acre, Rondônia (AMACRO-II), and Amazonas (AM-I and AM-II), all of which originated from the earlier AMACRO-I subclade within the BR-2015–2024 lineage [60]. While direct experimental evidence linking reassortment to enhanced transmission is lacking, phylogenetic analysis of concatenated L, M, and S segments (Figure 2) shows that the co-circulation of divergent parental lineages and the establishment of this novel reassortant clade across multiple regions likely contributed to viral adaptation and the spread of OROV beyond its traditional endemic areas. Time-scaled phylogenetic tree based on concatenated Oropouche virus L, M, and S genome segments in Brazil. Branch colors indicate the Brazilian state where the virus is most likely to have originated. Black dots indicate branches with strong statistical support. Major clades are labeled. Small colored dots near the tips show the likely place of infection, and dots at the tips indicate where the sample was collected. Analysis of these sequences suggests that reassortment of viral segments contributed to the emergence of a novel clade and its geographic spread outside the Amazon, with subclades linked to urban centers in Acre, Rondônia (AMACRO-II), and Amazonas (AM-I and AM-II). Adapted from Gräf et al., Expansion of Oropouche Virus in Non-Endemic Brazilian Regions: Analysis of Genomic Characterisation and Ecological Drivers, Figure 4B, The Lancet Infectious Diseases, 2025; 25:379–389, with permission from Elsevier. RO, Rondônia; AC, Acre; AM, Amazonas, SC, Santa Catarina; PE, Pernambuco; ES, Espírito Santo; RJ, Rio de Janeiro. Clinical features of uncomplicated, self-limiting Oropouche fever Summary of overall clinical manifestations and potential complications is shown in Figure 3. The incubation period of OROV-infected patients has been reported as 3–4 days with a range of 1–10 days [61]. The disease typically presents with an abrupt onset. According to a meta-analysis by Wang Z. et al. of 4,196 patients with OROV infection from 6 countries across the globe reported between 1993 and 2023 across 15 studies, the most prevalent symptoms of Oropouche fever were fever (typically 39 to 40°C)(100%), headache (95%), myalgia (72%), and dizziness (69%). Other common manifestations included anorexia (59%), arthralgia (58%), retro-orbital pain (56%), neck or back pain (48%), fatigue (45%), and nausea or vomiting (44%). Less frequent signs included photophobia (31%), pallor (28%), red eyes (27%), chills (26%), odynophagia (26%), diarrhea (17%), sore throat and nasal congestion (15%), cough (14%), pruritus (12%), rash (11%), jaundice (10%), abdominal pain (7%), and respiratory distress (1%) [62]. Although clinical symptoms of Oropouche fever usually last 2 to 5 days, approximately 60% patients experience recurrence 1 to 10 days after recovery, with headache, myalgia, and asthenia, sometimes accompanied by low-grade fever, and in certain cases, dizziness, headache, and asthenia may persist for several weeks to a month [43,44,63]. Maculopapular or rubella-like rashes can occur in the trunks, arms, and less commonly on the thighs in OROV-infected patients, typically appearing 3–6 days after fever onset and resolving within 2–3 days as a transient cutaneous manifestation [48,64]. A study of 75 OROV patients and 60 healthy donors from Pará (2006) and Amapá (2009), Brazil, found consistently elevated IFN-α and CXCL8 in infected individuals, with late seroconverters (around day 8 post-onset) showing transient IL-6 and CXCL10 peaks at 1–7 days, and early seroconverters (1–3 days post-onset) exhibiting transient CCL2 and IL-5 elevations at 8–11 days [65]. Another study reported that OROV-infected patients with acute fever in Brazil in 2024 exhibited transient elevations of CCL11, CXCL10, IFN-γ, IL-1RA, and IL-10 on day 1 [66]. These observations indicate that proinflammatory and anti-inflammatory cytokines, Type I and II interferons, and chemokines are actively involved in the acute febrile response in these patients. Clinical features of patients infected with Oropouche virus. Symptomatic patients infected with Oropouche virus (OROV) typically experience febrile illness lasting 2–5 days. Some patients may develop recurrent febrile episodes or neuroinvasive disease before recovery. During the 2023–2025 outbreak, a subset of patients exhibited Guillain–Barré syndrome lasting several weeks, acute hemorrhagic fever – like illness with rapid progression to multiorgan failure, or maternal infection resulting in miscarriage, fetal demise, or fetal malformations, including microcephaly. Neuroinvasive Oropouche virus infection Analysis of 22 patients with OROV – associated neurological manifestations during the 1980 outbreak in the state of Pará, Brazil showed that illness typically begins with febrile symptoms, including fever, headache, malaise, myalgia, and arthralgia, with neurological symptoms developing a few days later, often during the second week of illness [63]. Headache and dizziness may intensify several days after onset, and additional neurological signs such as neck stiffness, diplopia, nystagmus, difficulty maintaining upright posture, confusion, attention deficits, and hallucinations can appear between days 5 and 14 after symptom onset [63]. Three additional patient cases in Brazil further illustrate this clinical course, showing that systemic symptoms are often followed by seizures, dizziness, altered gait, muscle weakness, positive Romberg sign, photophobia, vomiting, high fever, and, in one case, mild lower-limb spasticity with a positive Babinski sign [67,68]. Among the three patients, one exhibited cerebrospinal fluid finding with mild to moderate lymphocytic pleocytosis, slightly elevated protein, and normal glucose, while cerebral computed tomography revealed cortical edema [67]. Recurrent neuroinvasive disease was also reported in a patient in the United States who had returned from Panama in 2025 [69]. The 19-year-old woman, with no underlying medical conditions, initially experienced fever, malaise, and diarrhea that resolved within five days. On day 12, she developed severe positional headache, neck and spinal stiffness, blurred vision, and dizziness, which improved by day 25, followed by a recurrence of severe headache, fever, neck stiffness, blurred vision, dizziness, weakness, and unsteadiness on day 32. After four days, the patient was discharged from the hospital in stable condition, with no recurrence of symptoms [69]. It was shown that human brain slice cultures exposed to OROV BeAn19991 supported widespread viral replication by 48 hours post-infection, with infection observed in microglia (~35%) and neurons (~2%) but not in astrocytes, accompanied by increased TNF-α levels and elevated microglial activation markers, including iNOS mRNA and HLA-DR protein [70]. Other studies using forebrain organoids, which consist mainly of neurons, have shown that OROV strains TR9760 and OROV240023 infect both SOX2+ neural progenitors and SOX2– differentiated neurons [71]. Guillain-Barré syndrome associated with Oropouche fever In addition to neuroinvasive disease affecting the central nervous system, OROV infection has also been associated with Guillain – Barré Syndrome, a post-infectious autoimmune neuropathy [72]. In 2024, Cuba experienced a sharp rise in Guillain-Barré Syndrome cases following the rise of Oropouche fever, with most GBS cases occurring shortly after the peak of OROV transmission. Among these, 65 patients (27.9%) tested RT-PCR positive for OROV, supporting a temporal association between infection and neurological outcomes [73]. In three cases reported from Cuba [74], patients initially experienced fever, malaise, headache, arthralgia, and abdominal pain for 4–6 days, followed by resolution of systemic symptoms. However, 10–11 days after onset, patients remained conscious and oriented without signs of meningeal irritation, while exhibiting muscle weakness, diminished deep-tendon reflexes, and neurological signs such as paresthesias in the extremities, cramps or tingling in fingers and toes, facial asymmetry, and gait disturbance. The patients remained hospitalized for 22–26 days and were discharged fully recovered, with no sequelae. Fatal cases of Oropouche fever in humans The clinical features of two fatal OROV infections in Bahia, Brazil, in 2024 were documented [75]. The first patient, a 24-year-old woman with no underlying conditions, initially presented with fever, headache, retroorbital pain, myalgia, severe abdominal pain, diarrhea, nausea, vomiting, and blurred vision, and was admitted 3 days after symptom onset due to worsening symptoms. During hospitalization, she developed ocular edema, psychomotor agitation, hypotension, and oxygen desaturation, and died on day 4 after symptom onset. The second patient, a 21-year-old woman with no underlying conditions, initially presented with fever, myalgia, headache, retroorbital pain, lower limb pain, asthenia, and joint pain. Four days after symptom onset, she developed weakness, drowsiness, vomiting, a rash with purple spots, and bleeding from the nose, gums, and vagina, prompting hospital admission. On examination, she exhibited cyanosis of extremities, persistent vomiting, bleeding gums and epistaxis, vaginal bleeding, cold and clammy skin, and widespread petechiae. The patient died on day 5 after symptom onset. Laboratory results indicated rapid progression of multiple-organ failure within hours, with anemia, thrombocytopenia, severe coagulopathy, hepatic and renal dysfunctions, while viral RNA was detected from the blood samples. During the 2024 outbreak in Espírito Santo, Brazil, a fatal case was reported in a 61-year-old woman with a history of hypertension and obesity [76]. The patient experienced three days of fever and acute dyspnea and succumbed to the infection from multiorgan failure, including acute respiratory distress, coagulopathy, and renal failure, within 11 hours of admission. Between 1 and 7 hours after admission, the patient’s blood tests revealed progressive leukocytosis with neutrophilia, declining platelet counts, worsening renal function, and the onset of severe coagulopathy. Postmortem examination revealed multifocal hepatic necrosis with infiltration of multinucleated inflammatory cells, extensive acute tubular necrosis in the kidneys, and interstitial pneumonitis characterized by moderate inflammatory infiltrates, marked edema, and hyaline membrane formation. Immunohistochemistry detected OROV antigens in hepatocytes and leukocytes in liver, mononuclear cells in alveolar spaces, and renal tubular epithelium. All fatal OROV cases exhibited acute coagulopathy and rapid progression to multiorgan failure, highlighting the urgent need for early diagnosis, effective supportive care, and further research into the pathogenesis, risk factors, and clinical management. Oropouche fever in pregnant patients During the 1980 OROV outbreak in Manaus, two of nine pregnant patients experienced miscarriage at two months of gestation [44]. Although this early study suggested a potential impact of OROV infection on pregnancy, detailed etiological investigations directly linking OROV to miscarriage were not reported until recently. During the 2023–2025 OROV outbreak, the virus was increasingly recognized as a cause of adverse pregnancy outcomes, suggesting the occurrence of vertical transmission in Brazil and other parts of South America [77–82]. Accumulating evidence demonstrates that maternal infection during pregnancy can lead to miscarriage, intrauterine fetal demise, stillbirth, congenital anomalies, and, in some cases, neonatal infection [79,80,83]. Case series and outbreak reports document confirmed or suspected vertical transmission in at least 18 pregnancies between 2016 and 2025 (Table 4) [41]. These include nine cases of microcephaly [77,78], four cases of intrauterine fetal demise [83,84], two cases of miscarriages [79,83], two cases of antepartum OROV infections [79,83], and one case of neonatal brain malformation [79]. Major clinical manifestations in affected neonates include microcephaly, lissencephaly, ventriculomegaly, agenesis of the corpus callosum, and ocular abnormalities. Postmortem and histopathological analyses further reveal systemic fetal and placental infection, vasculopathy, and central nervous system damage [77,81,85]. Despite the high risk of fetal complications, outcomes are variable: some pregnancies result in healthy, asymptomatic neonates without detectable viral RNA, while intrapartum transmission can occur if maternal viremia coincides with delivery [79,80,83]. Vertical transmission was confirmed by detecting OROV RNA in maternal serum, placental tissue, umbilical cord blood, and fetal or neonatal tissues using RT-qPCR, often supported by OROV-specific IgM antibodies in maternal or neonatal serum, demonstrating transplacental passage of the virus from mother to fetus or neonate [83,84]. In experimental settings, trophoblast stem cell derived organoids, including cytotrophoblasts, syncytiotrophoblasts, and co-cultures of both, were permissive to OROV BeAn19991 infection, indicating that these cells are potential targets for OROV in the placenta [86]. These findings highlight the neurotropic and teratogenic potential of OROV in neonates and underscore the importance of considering maternal febrile illnesses during pregnancy in the differential diagnosis to enable preventive measures against vertical transmission of OROV. Table 4.Oropouche virus infection during pregnancy.YearsLocationsMaternaldiseasesNeonatal/fetaloutcomeDiagnosisRef1980Manaus (AM)NRMiscarriage, 8 wkNR441980Manaus (AM)NRMiscarriage, 8 wkNR442016Rio Branco (AC)Rash, 1st trim.Microcephaly, Died 2 dIgM+, neonate772016Rio Branco (AC)AsymptomaticMicrocephalyIgM+, neonate772018Augusto Corrêa (PA)Febrile, 1st trim.MicrocephalyIgM+, mother & neonate772024Feijó (AC)Febrile, 2nd trim.MicrocephalyIgM+, mother & neonate772024Rio Branco (AC)Febrile, 1st trim.Microcephaly, arthrogryposisIgM+, mother & neonate772024Sena Madureira (AC)Febrile, 1st trim.Microcephaly, arthrogryposis, Died at 47 days-oldIgM+, mother & neonate; RT-qPCR+, neonate772024Rio Branco (AC)Febrile, 2nd trim.MicrocephalyIgM+, mother & neonate782024Rio Branco (AC)Febrile,1st trim.Microcephaly, Died at 47 days-oldIgM+, mother & neonate; RT-qPCR+, neonate782024Rio Branco (AC)Febrile, 2nd trim.Microcephaly, arthrogryposisIgM+, mother & neonate782024Maciço de Baturité region (CE)Febrile, 1st trim.Fetal demiseRT-qPCR+, neonate842024Jaqueira (PE)Febrile, 1st trim.Miscarriage, 8 wkIgM+, mother; RT-qPCR+, mother832024Maraial (PE)Febrile, 38 wk gest.Fever, 3 days-oldIgM+, mother & neonate; RT-qPCR+, mother832024Machados (PE)Febrile, 38 wk gest.Fetal demise, 38 wkIgM+, mother832024Ipojuca (PE)Febrile, 29 wk gest.Fetal demise, 29 wkRT-qPCR+, mother & fetus832024Rio Formoso (PE)Febrile, 30 wk gest.Fetal demise, 30 wk and 5 dIgM+, mother; RT-qPCR+, fetus832024ESFebrile, 7 wk gest.Miscarriage, 8 wkRT-qPCR+, mother792024ESFebrile, 7 wk gest.Corpus callosum dysgenesisRT-qPCR+, neonate792024ESFebrile, 38 wk gest.Fever, 4 days-oldRT-qPCR+, neonate79Abbreviations: AC (Acre), AM (Amazonas), CE (Ceará), ES (Espírito Santo), PA (Pará), PE (Pernambuco). Trim, trimester; Gest, gestation; NR, not reported. Oropouche virus infection during pregnancy. Abbreviations: AC (Acre), AM (Amazonas), CE (Ceará), ES (Espírito Santo), PA (Pará), PE (Pernambuco). Trim, trimester; Gest, gestation; NR, not reported. Persistent OROV infection in patients Although OROV RNA can be detected in patients’ serum samples by RT-PCR [87,88], infectious virus was also isolated from leukocytes (buffy coat) obtained from the whole blood of a febrile patient two days after symptom onset in São Paulo, Brazil, in 2010 [89]. In addition, OROV RNA was detected in saliva and urine samples from patients in Bahia, Brazil, in 2016 [21]. More recently, during the 2024 outbreak, prolonged detection of OROV RNA was reported in the bodily fluids of travelers returning from Cuba. An Italian traveler returning from Cuba that year experienced an acute febrile illness lasting two days, with fever recurrence on day 4 after symptom onset, and showed no rash or neurological abnormalities [90]. Although the patient recovered and was asymptomatic by day 10, OROV RNA remained detectable in serum on days 5 and 10, and in whole blood and urine on days 5, 10, 16, and 32. Replication-competent virus was also isolated from semen collected on day 16. Remarkably, low levels of viral RNA persisted for up to 86 days in semen and 135 days in whole blood [90,91]. Given that both pregnant women and fetuses are susceptible to OROV infection, evaluating the potential risk of sexual transmission during outbreaks is of critical importance [92]. Other travelers returning from Cuba in 2024 similarly exhibited prolonged viremia, presenting with a self-limiting febrile illness followed by extended OROV RNA detection in whole blood but not in serum for more than 10 weeks after symptom onset, suggesting viral persistence in host tissues [93,94]. Using THP-1 cells, it was shown that human macrophages, but not monocytes, are permissive to OROV infection; however, infected macrophages underwent pyroptosis within 24 to 48 hpi [95]. It will be important to identify the cell types that support prolonged OROV persistence in human patients. Although anti-OROV IgM and IgG are detectable during infection, it remains unclear how the virus evades neutralization and clearance [68,94] Animal models for Oropouche fever Mice Mice provide a versatile model for OROV infection, with age- and route-dependent susceptibility that may recapitulate features of human disease and immune responses. Mice (C57BL/6, BALB/c, SJL, and Swiss) inoculated with OROV via intraperitoneal (i.p.) or subcutaneous (s.c.) routes exhibit age-dependent susceptibility, with neonates developing severe disease while adults remain largely resistant [7,13,96,97]. In contrast, both infant and adult mice are highly susceptible to OROV following intracerebral (i.c.) inoculation [13]. One-day-old suckling BALB/c mice inoculated s.c. with OROV remained asymptomatic until 5 days post-challenge (dpc), after which 85% developed severe neurological disease or died between 5 and 8 dpc [98]. Affected mice exhibited halted growth, apathy, paralysis, and inability to suckle, with viral antigens and RNA primarily localized to NeuN-positive neurons in the brain and spinal cord but absent in the spleen and liver [98]. Viral dissemination throughout the brain was observed between 4 and 7 dpc [99]. Meanwhile, 3-week-old BALB/c mice subcutaneously infected with OROV exhibited reduced body weight gain at 2–5 days post-infection but survived during the experiment for 21 days. At 4 dpc, those infected mice displayed splenomegaly, leukopenia, thrombocytopenia, anemia, and elevated serum pro-inflammatory cytokines (TNF-α, IFN-γ). Liver histology showed inflammatory foci containing mononuclear and polymorphonuclear cells, along with elevated serum ALT and AST levels, indicating that the virus exhibits tropism for liver tissue in mice. The innate immune system is the key determinant of mouse resistance to OROV infection. In 5–6-week-old knockout C57BL/6 mice, type I IFN signaling was essential for protection, with 100% lethality observed in Ifnar−/− and Irf3−/− Irf5−/− Irf7−/− (triple knockout) mice, while partial susceptibility was seen in Ifnb−/− (17%), Mavs−/− (39%), Irf5−/− (39%), and Irf3−/− Irf7−/− (double knockout) (54%) mice [7,100]. In OROV-infected Ifnar−/− mice, viral replication reached high levels in the liver and spleen, with only rare detection in the brain and spinal cord at 4 dpc. Focal hepatocyte necrosis and viral antigen were observed in hepatocytes and splenic mononuclear cells, indicating that type I IFN signaling is important for restricting viral replication and limiting liver pathology [7]. Irf5−/− mice infected with OROV developed delayed and protracted disease, showing transient liver injury around 6 dpc and viral dissemination to the brain and spinal cord at 9–12 dpc, indicating that IRF-5 is important for controlling systemic spread and preventing neuropathogenesis [100]. In Ifnar−/− or Irf3−/− Irf5−/− Irf7−/− (triple knockout) mice, selective proinflammatory cytokines (IL-6, IL-12p40, G-CSF) and chemokines (MIP-1α, KC, RANTES) were elevated, whereas IL-1β and TNF-α remained unchanged, suggesting specific inflammatory cytokines are associated with the pathogenesis [7,100]. Pregnant C57BL/6J mice have been shown to be susceptible to infection with OROV [101]. Pregnant dams were subcutaneously inoculated with 2.42 × 105 TCID50 of OROV (recombinant BeAn19991 or the 240,023 Cuban 2024 strain) at embryonic days 4.5, 7.5, or 12.5, resulting in detectable viral RNA in maternal livers, placentas, and matched fetal tissues, as well as viral antigens in the placental labyrinth zone, while no fetal resorption, pregnancy loss, or malformations were observed [101]. Overall, adult mouse models of OROV infection exhibit systemic disease with mild to severe liver injury, thrombocytopenia, and selective IL-6 elevation, features that partially resemble those observed in human cases and may contribute to understanding systemic immunopathogenesis in OROV infection. Especially susceptible Ifnar−/− and Irf3−/− Irf5−/− Irf7−/− (triple knockout) mice can serve as valuable animal models for evaluating the protective efficacy of candidate vaccines and antiviral therapies against OROV. Vertical transmission of OROV in pregnant C57BL/6 mice indicates increased susceptibility of pregnant animals to infection, with placental tissues serving as a target for viral replication. Comparative studies of murine and human placental tissues could further clarify the mechanisms of OROV infection during pregnancy. Syrian golden hamsters Syrian golden hamsters (Mesocricetus auratus) are highly susceptible to OROV infection, developing severe systemic and neurological disease, making them a valuable model for studying viral pathogenesis and transmission. Adult hamsters are highly susceptible to i.c. or i.p. OROV inoculation, developing anorexia, ruffled fur, prostration, occasional hind-limb paralysis, and high brain viral titers, and dying 2–4 days post-infection [13]. The median lethal dose (LD50) of the prototype BeAn19991 strain was determined to be 105 ·6 TCID50 in three-week-old Syrian golden hamsters inoculated s.c [8]. Meanwhile, the LD50 of various OROV strains and Iquitos virus in 3–4-week-old Syrian hamsters inoculated i.p. were determined as follows: >7,000 PFU (BeH379693, OROV genotype I), 1 PFU (BeH544552, OROV genotype I), 45 PFU (MD023, OROV genotype II), >2,500 PFU (GML444477 and GML445252, OROV genotype III), and 4,220 PFU (IQT9924, Iquitos virus) [12]. Hamsters infected with BeAn19991 had peak viremia at 3 dpc, and exhibited reduced food and water intake, ruffled fur, fever, lethargy, shivering, ataxia, circling behavior, and occasional hind limb paralysis, ultimately succumbing between 4 and 11 dpc [8]. Histopathological analysis revealed focal hepatic necrosis with lymphomononuclear inflammatory infiltrates and meningoencephalitis characterized by microglial nodules, perivascular cuffs, and diffuse mononuclear infiltrates predominantly in the brainstem, while OROV antigen was detected in neurons and hepatocytes by immunohistochemistry [8]. Since OROV-infected hamsters develop high levels of viremia, this model has been used to study viral transmission via arthropod vectors [46,48]. Unlike mice, immunocompetent 3–4-week-old Syrian hamsters can develop lethal disease when infected with various OROV strains, exhibiting systemic viral replication that affects both the liver and the brain. However, it remains unclear whether the varying LD50 values of different OROV strains correspond to their virulence in humans. Data are still limited on how well the hamster model replicates human OROV infection and the relative virulence of different OROV strains. Nonhuman primates Nonhuman primates can be infected with OROV, often without overt clinical illness, providing insight into viremia, immune responses, and potential long-term protective immunity. Adult non-human primates including Trinidadian Cebus monkeys [13], patas monkeys, rhesus macaques, and African green monkeys (vervet and sabaeus) [102] were susceptible to OROV infection without overt clinical illness. Plasma viremia was detectable by day 2 postinfection, peaked on days 3 to 5, and was cleared by day 9. Viral RNA was occasionally found in nasal swabs and cerebrospinal fluids [102]. Even though high viremia was observed at 4–5 dpc, viral RNA was either undetectable or present at low levels in the monocytes and lymphocytes of infected patas monkeys, rhesus macaques, and African green monkeys. In contrast, monocyte-derived macrophages from these species supported productive OROV replication following in vitro infection. Infection induced robust type I IFN responses, proliferation of IgM+ B cells and NK cells, and neutralizing antibodies. Rechallenge of previously infected animals up to one year after primary infection resulted in little to no detectable viral RNA in plasma, indicating that primary OROV infection confers long-lasting protective immunity [102]. Although OROV has been naturally isolated from nonhuman primates such as Callithrix species [24,52,103], their clinical manifestations upon OROV infection have not been reported. Meanwhile, MDDV, an M-segment reassortant of OROV, was isolated from a moribund white-faced capuchin monkey (Cebus olivaceus) in Venezuela [56]. Further studies are needed to determine whether nonhuman primates serve as asymptomatic hosts for OROV and whether M-segment reassortment contributes to enhanced virulence of OROV in these hosts. Other animals Studies in guinea pigs, rabbits, and embryonated eggs demonstrate variable susceptibility to OROV [13]. In guinea pigs, i.c. infection caused hind-limb paralysis and occasional death, whereas i.p. inoculation produced no observable illness despite detectable neutralizing antibodies. Adult rabbits inoculated via i.c. or i.p. routes remained clinically healthy but developed neutralizing antibodies, indicating a subclinical immune response. Infection through the yolk sac of embryonated eggs was highly lethal after multiple passages, while amniotic sac inoculation did not affect embryos. Serological studies conducted in Pará, Brazil in 1975 detected hemagglutination-inhibition (HI) antibodies in wild birds of the families Cuculidae, Dendrocolaptidae, Formicariidae, and Troglodytidae (10–32.5% positive), in chickens (5.5% positive), and in wild rodents (1.2% positive) [104], as well as neutralizing antibodies against OROV in sheep, cattle, and dogs [105,106]. These findings suggest that wild birds, chickens, rodents, sheep, cattle, and dogs may be exposed to OROV or other antigenically related Simbuviruses in nature, although it remains unclear whether these animals become actively infected or contribute to viral transmission cycles. Viral determinants that govern virulence and vector-mediated transmission Gn and Gc proteins Orthobunyavirus glycoprotein spikes are composed of heterodimers of Gn and Gc proteins, and X-ray crystallography revealed that the N-terminal trimeric head of the OROV Gc protein closely resembles that of Bunyamwera virus (BUNV) [107,108]. Lrp1 (low-density lipoprotein receptor – related protein 1) is a highly conserved transmembrane protein essential for endocytosis, signaling, lipoprotein metabolism, blood – brain barrier maintenance, and angiogenesis, which is ubiquitously expressed in the liver, placenta, and brain. It was demonstrated that Lrp1 is a critical host factor for both Rift Valley fever virus (RVFV) and OROV infection [109,110]. Although elevated liver enzymes are not commonly observed in OROV-infected patients, histological examination of a deceased patient revealed abundant viral antigens in hepatocytes [76]. Moreover, the occurrence of meningoencephalitis and placental infection in OROV-infected patients suggests that OROV entry via the Lrp1 receptor plays a significant role in disease pathogenesis. The interaction between OROV Gn and Gc proteins and Lrp1 has not been fully elucidated; further characterization could provide fundamental insights into viral tissue tropism and the variability of pathological outcomes among patients. Meanwhile, during virus assembly and budding, OROV uniquely recruits the Endosomal Sorting Complex Required for Transport (ESCRT) machinery to Golgi membranes. There, the protein CHMP6 builds a scaffold to support virion formation, and VPS4 helps pinch off the membrane so new virions can exit the cell, even though OROV does not encode a viral late domain [111]. Moreover, the two transmembrane domains of Gn are required for its trafficking to the Golgi and for secretion, and Gn must be coexpressed with Gc to ensure proper folding and ER-to-Golgi transport [111], underscoring that intact Golgi function is essential for productive OROV replication. Nss protein The OROV NSs gene (91 amino acids) is encoded within the S segment, overlapping the open reading frame of the N gene (Figure 4A). Using a reverse genetics system for the OROV BeAn19991 strain, two recombinant OROV (rOROV) mutants with C-terminally truncated NSs genes were generated, expressing either 16 or 82 amino acids [112]. Both NSs mutants produced smaller plaques in BHK-21 cells and exhibited roughly a 1-log10 decrease in viral replication in Vero E6 cells, as well as more than a 1-log10 reduction in replication in type I IFN-competent A549 cells, compared with the parental rOROV. In contrast, N protein levels appeared higher in Vero E6 cells infected with the NSs mutants than in those infected with the parental virus [112]. Notably, A549 cells produced abundant type I IFNs following infection with the rOROV NSs mutants, but not with the parental rOROV, demonstrating that the OROV NSs protein functions as an antagonist of type I IFN responses [112]. The NSs protein of OROV encodes a putative nucleolar localization signal and colocalizes with nucleophosmin (NPM1), an abundant, multifunctional phosphoprotein predominantly found in the nucleolus of proliferating cells (Figure 4B) [113]. During OROV infection, NPM1 undergoes extensive redistribution from the nucleoli to the nucleoplasm. Notably, Vero cells infected with wild-type OROV also experience posttranslational degradation of the host RNA polymerase II (RNAP II) RPB1 subunit. The RVFV MP-12 strain encodes an independent NSs ORF, making it suitable for the expression of OROV NSs, including epitope-tagged variants. Interestingly, OROV NSs expressed from MP-12 induces only partial NPM1 redistribution and selectively degrades the hyperphosphorylated form of RPB1 (IIo). Furthermore, OROV NSs fused with a C-terminal Strep-Flag tag, but not a Flag tag alone, failed to induce RPB1 degradation, despite exclusive co-localization with NPM1 within nucleoli [113]. Expression of Oropouche virus NSs and NSm genes. (A) Genome organization of OROV. The tripartite negative-sense RNA genome (L, M, and S segments) is shown. The NSs gene (91 aa) is encoded within the S segment in an overlapping reading frame with the nucleocapsid (N) gene, whereas the NSm gene (146 aa) is encoded within the M segment polyprotein, which is co-translationally cleaved to generate Gn, NSm, and Gc. (B) Functions of the NSs protein in host transcriptional suppression and immune evasion. NSs localizes to the nucleolus via a putative nucleolar localization signal and colocalizes with nucleophosmin (NPM1), inducing its redistribution to the nucleoplasm. NSs also promotes posttranslational degradation of the RNA polymerase II large subunit (RPB1), particularly the hyperphosphorylated form (IIo), resulting in global inhibition of host transcription. Functionally, NSs acts as a type I interferon (IFN-I) antagonist, as viruses lacking NSs induce robust IFN-I responses and show attenuated replication in IFN-competent cells. (C) Membrane topology and processing of the NSm protein. NSm is derived from the M segment glycoprotein precursor following signal peptidase cleavage (indicated by arrows). The mature NSm protein contains five domains (I–V), including an ectodomain (II), two transmembrane domains (III and V), and a cytoplasmic domain (IV). Although NSm is dispensable for viral replication in mammalian and mosquito cell culture, studies in related orthobunyaviruses suggest a role in viral dissemination within insect vectors, particularly in midgut infection and spread. Although the mechanistic link between NSs association with NPM1, NPM1 redistribution from nucleoli, and RNAP II RPB1 degradation remains unclear, similar functions have been reported for NSs proteins from other orthobunyavirus species. Schmallenberg virus (SBV) NSs, which shares 57.6% amino acid identity, colocalizes with NPM1, causing its redistribution from the nucleolus to the nucleoplasm, and promotes posttranslational degradation of RNAP II RPB1 [114,115]. Beyond the Simbu group viruses, BUNV and La Crosse virus (LACV) also inhibit cellular RNAP II through the actions of their NSs proteins. The BUNV NSs protein localizes to both the cytoplasm and nucleus [116] and inhibits the serine 2 phosphorylation of the C-terminal domain (CTD) of RPB1, likely through the interaction with Mediator protein MED8 [117,118]. LACV NSs protein affects the phosphorylation of the RNAP II RPB1 CTD at both serine 2 and serine 5, leading to the degradation of the hyperphosphorylated IIo form [119], while wildtype LACV infection induces the redistribution of Elongin C from the nucleoli [120]. These findings highlight the remarkable functional similarity of NSs proteins across the listed orthobunyaviruses in mammalian cells, and NSs-mediated transcriptional suppression likely contributes to viral evasion of host innate immune responses. NSm protein The OROV M segment encodes a single ORF for a glycoprotein precursor, which undergoes co-translational cleavage to generate Gn, NSm, and Gc (Figure 4C). After the cleavage from the domain I, the OROV NSm protein (146 amino acids) consists of an ectodomain (domain II), a transmembrane domain (domain III), a cytoplasmic domain (domain IV), and a second transmembrane domain (domain V) [121]. Using a reverse genetics system for the OROV BeAn19991 strain, rOROV lacking entire NSm genes was generated [112]. This NSm deletion mutant replicates as efficient as parental rOROV in mammalian cells (Vero E6 and A549) and mosquito cells (U4.4 and Aag2) [112]. Since the NSm protein is non-essential for OROV replication in cultured cells, the NSm gene cassette was repurposed for the expression of the fluorescent reporter gene ZsGreen (ZsG) by fusing it with the self-cleaving Thosea asigna virus 2A (T2A) sequence [122]. The resulting virus, rOROVMZsG, formed smaller plaques in Vero E6 cells and showed roughly a 1-log10 reduction in viral replication in both Vero E6 and A549 cells, yet it retained virulence in Ifnar− /− mice (B6(Cg)-Ifnar1tm1.2Ees/J), causing multifocal hepatic necrosis comparable to that induced by the parental rOROV [122]. Although the function of NSm in OROV remains completely unknown, the functions of NSm in other orthobunyaviruses have been investigated. Recombinant BUNV lacking NSm exhibited impaired viral spread in midgut epithelial cells and reduced viral dissemination in Aedes aegypti mosquitoes following an infectious blood meal [123]. Notably, infection foci in midgut cells were restored by in trans expression of NSm-V5, followed by oral infection with NSm-deficient BUNV, demonstrating that BUNV NSm functions as a critical viral determinant required for efficient viral spread within the mosquito midgut. Meanwhile, the replication of recombinant SBV lacking NSm was assessed in C. sonorensis following blood meal feeding [124]. At 6 dpi, 2.07% of midges fed with parental rSBV and 1.92% of midges fed with rSBV lacking NSm exhibited higher S-segment RNA copy numbers compared to 0 dpi, as determined by RT-qPCR using total RNA extracted from whole-body homogenates of individual midges. Although the overall infection rate of rSBV in C. sonorensis was low, the specific function of the SBV NSm protein in viral replication and spread within the midge remains unclear. Perspectives Oropouche fever imposes significant socioeconomic burdens in endemic regions, as high morbidity reduces workforce productivity and strains already limited public health systems, increasing both direct and indirect healthcare costs and undermining long-term economic stability [125]. The circulation of OROV in wild animal reservoirs and sylvatic vectors, together with the presence of competent vectors in urban settings and the ongoing effects of climate change, urbanization, and deforestation, may elevate the risk of spillover into urban populations and subsequent outbreaks. Reassortant OROV strains containing M segments derived from an unknown Simbu virus have been detected in humans (IQTV, MDDV), wild primates (PDEV, MDDV), and a ring-tailed coati (JATV) [10–12,55,56]. Notably, the OROV BR-2015–2024 strain responsible for the 2023–2025 outbreak was also a reassortant, carrying S and L segments from the OROV PE/CO/EC-2008–2021 clade circulating in Peru, Colombia, and Ecuador, and an M segment related to the OROV BR-2009–2018 clade detected in Brazil [59]. These findings underscore the importance of monitoring circulating OROV reassortant strains in humans, vectors, and wildlife, and assessing the virological and pathological properties of emergent M-segment reassortants to inform public health risk assessment [126]. Although increasing evidence of OROV infection, including severe complications and deaths in humans, emerged across expanded geographical regions during the 2023–2025 outbreak, our understanding of the virological changes associated with pathogenesis and widespread viral transmission remains limited. The absence of animal models that faithfully replicate human disease further limits the study of OROV pathogenesis. For example, the LD50 varies considerably among OROV strains in hamsters, suggesting that viral factors, such as the property of specific virus stocks, and host-related experimental conditions, including genetic background, age, and health status, may strongly influence the observed virulence phenotype. Immunodeficient mice such as Ifnar− /− are useful for evaluating candidate vaccines and antivirals. However, a limitation of this model is their broad susceptibility to OROV, regardless of viral strain, which may restrict its use in studies assessing strain-specific virulence. Future research should prioritize developing animal models, including pregnant models to study vertical and sexual transmission, and elucidating the cellular and molecular mechanisms underlying OROV virulence in the brain, liver, and placenta. The NSs protein acts as an antagonist of type I IFNs and promotes the degradation of RNA polymerase II [112,113]. OROV NSs can co-localize with NPM1, causing its redistribution from the nucleolus to the nucleoplasm. Infected Vero cells display extensive cytopathic effects and undergo cell death. Meanwhile, NSs expression is minimal in human THP-1 macrophages, reflecting restricted viral replication in these cells. Infected macrophages, however, activate NLRP3 inflammasomes and caspases 1 and 3, leading to pyroptosis accompanied by IL-1β secretion [95]. Because some OROV-infected patients harbor infectious viruses in blood cells and sperm, it is important to understand the host cell types and virological factors that allow the virus to persist for months. The molecular functions of the OROV NSm protein remain poorly understood, although its role in viral replication in the vector midgut has been demonstrated for BUNV. Because maintaining C. paraensis for experimental studies is challenging, North American C. sonorensis was tested for susceptibility to OROV infection. OROV efficiently disseminates in C. sonorensis, supporting its use as a surrogate for C. paraensis. Although the role of mosquitoes as vectors has not been confirmed, repeated isolation of OROV from mosquitoes indicates exposure to virus-containing blood. It is therefore important to evaluate the functional role of OROV NSm in viral dissemination and transmission by both midges and mosquitos. The 2023–2025 OROV outbreak has highlighted the growing public health impact of this virus, underscoring the need for more effective measures to prevent transmission and severe disease. No licensed vaccines or antiviral therapies are currently available for OROV infection. To date, one vaccine candidate, a replication-competent vesicular stomatitis virus (VSV) in which the endogenous glycoprotein is replaced with the OROV GPC, has been reported to reduce clinical signs and viral loads following challenge with wild-type OROV BeAn19991 in 6-week-old C57BL/6 mice [127]. Although ribavirin shows minimal effect on OROV replication [97], several antiviral candidates have been identified that effectively inhibit OROV, including acridones [128], wedelolactone [129], 4’-fluorouridine [130], lysergol [131]. It is important to strengthen our knowledge of OROV virology, pathology, and epidemiology, and to support the development of effective countermeasures, including vaccines and antiviral therapeutics. Acknowledgements We thank Figure images from Gräf et al. The Lancet Infectious Diseases, 2025; 25:379–389 for the material used in Figure 2D, and Shutterstock and BioRender.com for providing the material used to create the illustrations in Figure 1. Funding Statement This study was supported by the Data Acquisition Grant from the Institute for Human Infection and Immunity at The University of Texas Medical Branch at Galveston. Disclosure statement No potential conflict of interest was reported by the author(s). References